Racial difference in sarcoidosis mortality in the United States

Chest

Volumn 147, Issue 2, 2015, Pages 438-449

  Mirsaeidi, Mehdi ^a   Machado, Roberto F ^a   Schraufnagel, Dean ^a   Sweiss, Nadera J ^b   Baughman, Robert P ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE RESPIRATORY FAILURE; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; ASTHMA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATYPICAL MYCOBACTERIOSIS; CAUCASIAN; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; ETHNIC DIFFERENCE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIVER FAILURE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; RESPIRATORY ARREST; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEPTICEMIA; SEX RATIO; TRAFFIC ACCIDENT; TUBERCULOSIS; UNITED STATES; VERY ELDERLY; ETHNOLOGY; HYPERTENSION, PULMONARY; LUNG SARCOIDOSIS; RESPIRATORY FAILURE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ACCIDENTS, TRAFFIC; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COMORBIDITY; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84922244506     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1120     Document Type: Article

References (34)

1. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011; 305 ( 4): 391-399.
2. Westney GE, Judson MA. Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics. Clin Chest Med. 2006; 27 ( 3): 453-462.
3. Statement on sarcoidosis. Joint Statement of the American Th oracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160 ( 2): 736-755.
4. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial diff erences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997; 145 ( 3): 234-241.
5. Rasmussen ER. Re: "Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. " Am J Epidemiol. 2000; 151 ( 9): 938.
6. Kajdasz DK, Judson MA, Mohr LC Jr, Lackland DT. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am J Epidemiol. 1999; 150 ( 3): 271-278.
7. Sartwell PE, Edwards LB. Epidemiology of sarcoidosis in the US Navy. Am J Epidemiol. 1974; 99 ( 4): 250-257.
8. Baughman RP, Teirstein AS, Judson MA, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001; 164 ( 10 pt 1): 1885-1889.
9. Minus HR, Grimes PE. Cutaneous manifestations of sarcoidosis in blacks. Cutis. 1983; 32 ( 4): 361-363.
10. Judson MA, Baughman RP, Th ompson BW, et al; ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20 ( 3): 204-211.
11. Foreman MG, Mannino DM, Kamugisha L, Westney GE. Hospitalization for patients with sarcoidosis: 1979-2000. Sarcoidosis Vasc Diff use Lung Dis. 2006; 23( 2): 124-129.
12. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011; 183 ( 11): 1524-1530.
13. Gerke AK, Yang M, Tang F, Cavanaugh JE, Polgreen PM. Increased hospitalizations among sarcoidosis patients from 1998 to 2008: a population-based cohort study. BMC Pulm Med. 2012; 12: 19.
14. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med. 1996; 100 ( 4): 423-427.
15. Centers for Disease Control and Prevention. CDC WONDER website. http://wonder. cdc. gov. Accessed June 15, 2014.
16. Mirsaeidi M, Machado RF, Garcia J, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a populationbased comparative study. PLoS One. 2014;9(3):e91879.
17. Centers for Disease Control and Prevention. Multiple cause of death 1999-2011. CDC WONDER website. http://wonder. cdc. gov/wonder/help/mcd. html. Accessed July 21, 2013.
18. Moriyama IM. Mortality from sarcoidosis in the United States. Am Rev Respir Dis. 1961;84(5 pt 2):116-119.
19. Reich JM. Course and prognosis of sarcoidosis in African-Americans versus Caucasians. Eur Respir J. 2001; 17 ( 4): 833.
20. Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998; 13 ( 3): 166-173.
21. Geographical variations in the incidence of sarcoidosis in Great Britain: a comparative study of four areas. A report to the Research Committee of the British Th oracic and Tuberculosis Association. Tubercle. 1969; 50 ( 3): 211-232.
22. Benatar SR. Sarcoidosis in South Africa. A comparative study in whites, blacks and coloureds. SAfr Med J. 1977; 52 ( 15): 602-606.
23. Gillum RF. Sarcoidosis in the United States-1968 to 1984. Hospitalization and death. J Natl Med Assoc. 1988; 80 ( 11): 1179-1184.
24. The Henry J. Kaiser Family Foundation. Population distribution by race/ethnicity (based on Census Bureau's March 2012 and 2013 current population surveys). The Henry J. Kaiser Family Foundation website. http://kff. org/other/state-indicator/ distribution-by-raceethnicity. Accessed June 15, 2014.
25. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Minambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014; 6 ( 1): 9-20.
26. Boruchowicz A, Maunoury V, Crinquette JF, Cappoen JP. Diabetes: an ignored complication of sarcoidosis? Am J Gastroenterol. 1995; 90 ( 4): 681.
27. Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014; 2 ( 2): 123-130.
28. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006; 129 ( 5): 1246-1252.
29. Guskowski J, Hawrykiewicz I, Zych D, Wojtczak A, Zieliski J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration. 1984; 46 ( 1): 26-32.
30. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010; 138 ( 5): 1078-1085.
31. Maimon N, Salz L, Shershevsky Y, Matveychuk A, Guber A, Shitrit D. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis. 2013; 17 ( 3): 406-411.
32. Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014; 145 ( 4): 810-817.
33. Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diff use Lung Dis. 2011; 28 ( 2): 139-145.
34. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in US Medicare benefi-ciaries. Am J Respir Crit Care Med. 2012; 185 ( 8): 881-886.